Physician

David Hai Ru Chang, MD

According to 2025 Medicare claims, David Chang, MD (NPI: 1518170083) practices advanced heart failure and transplant cardiology in the Los Angeles-Long Beach-Glendale, CA market, with the plurality of this provider's patient population coming from Los Angeles, CA. This provider's primary affiliated billing organization is CEDARS-SINAI MEDICAL CARE FOUNDATION (NPI: 1316984388; TIN: 954457756) and primary practice location at 90211-2930. Chang is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604) and Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Chang's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 520 traditional Medicare patients, billed 1,745 HCPCS/CPT codes, and received $123,785 in Medicare payments. The top billing code was 93306 (Ultrasound of heart with color-depicted blood flow, rate, direction and valve function). Part D data shows 2,317 prescription claims across 370 beneficiaries totaling $1,150,559 in drug costs, led by Vyndamax (Tafamidis). DME data shows 388 claims. Open Payments data shows 2 records totaling $65. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $654,602 to $1,150,559. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $1,962 and ending at $1,157.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	532	1,876	$150,526
2016	505	1,858	$142,019
2017	555	1,850	$144,845
2018	531	1,821	$135,031
2019	542	1,770	$137,073
2020	466	1,726	$125,952
2021	518	1,956	$144,506
2022	558	1,829	$136,448
2023	581	2,027	$145,134
2024	520	1,745	$123,785

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	415	4,199	$654,602
2016	431	3,566	$674,894
2017	449	3,681	$493,396
2018	439	3,184	$355,769
2019	412	2,545	$331,568
2020	395	2,552	$270,578
2021	388	2,211	$292,160
2022	368	2,133	$496,996
2023	397	2,333	$1,232,810
2024	370	2,317	$1,150,559

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	719	3,790	$413,020
2016	646	2,620	$250,553
2017	614	2,725	$217,045
2018	500	2,245	$152,310
2019	292	1,197	$84,644
2020	170	663	$28,799
2021	171	576	$20,163
2022	135	563	$41,449
2023	132	577	$16,179
2024	109	388	$6,356

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	146	147	$146
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	143	196	$97
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	335	517	$64
99231	Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes	59	150	$41
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	89	113	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Vyndamax	Tafamidis	24	720	$539,820
Eliquis	Apixaban	159	9,188	$176,951
Jardiance	Empagliflozin	19	1,650	$31,665
Xarelto	Rivaroxaban	26	1,565	$28,274
Entresto	Sacubitril/Valsartan	19	1,250	$24,981

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	36	125	$1,568
J7507	Tacrolimus, immediate release, oral, 1 mg	N	24	80	$1,320
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	31	71	$1,299
J7517	Mycophenolate mofetil, oral, 250 mg	N	18	47	$868
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	12	$827

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$65	Medtronic, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for David Hai Ru Chang, MD?

Tedicare shows public-source Medicare data for David Hai Ru Chang, MD (NPI 1518170083), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does David Hai Ru Chang, MD have ACO affiliation data?

David Hai Ru Chang, MD is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604) and Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to David Hai Ru Chang, MD?

David Hai Ru Chang, MD is linked to CEDARS-SINAI MEDICAL CARE FOUNDATION (billing NPI 1316984388) in the available physician profile data.

Does David Hai Ru Chang, MD have Open Payments data?

David Hai Ru Chang, MD has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.